

## DAFTAR PUSTAKA

- Abbas AK. 2012. Innate immunity. In: Abbas AK, Lichtman AH, Pillai S, editors. Cellular and molecular immunology. 7th edition. Philadelphia: Saunders Elsevier. hlm. 55-88.
- Alcon A, Fabregas N, Torres A. 2005. Pathophysiology of pneumonia. *Clin Chest Med*. vol. 26. hlm. 39-46
- Amir M, Liu K, Zhao EP, Czaja MJ . 2012. Distinct functions of JNK and c-Jun in oxidant-induced hepatocyte death. *J Cell Biochem* 113(10):3254–3265.
- Armitage, K. and Woodhead, M. 2007. 'New guidelines for the management of adult community-acquired pneumonia', *Current Opinion in Infectious Diseases*, 20(2), hlm. 170–176.
- Armstrong, G. L., Conn, L. A. and Pinner, R. W. 1999, 'Trends in infectious disease mortality in the United States during the 20th century', *Journal of the American Medical Association*, 281(1), hlm. 61–66.
- Baratawidjaja GK, Rengganis I. 2009. *Imunologidasar*. Edisi ke-8. Jakarta: FKUI. hlm. 226-8.
- Bachman, M. A. *et al.* 2011. 'Klebsiella pneumoniae Yersiniabactin Promotes Respiratory Tract Infection through Evasion of Lipocalin 2', *Infection and Immunity*, 79(8), hlm. 3309–3316..
- Baretta AA, *et al.* 2020. Propolis and its potential against SARS-CoV-2 infection mechanisms and COVID-19 disease: Running title: Propolis against SARS-CoV-2 infection and COVID-19. *Biomedicine & Pharmacotherapy*, 131, 110622. <https://doi.org/10.1016/j.biopha.2020.110622>
- Barners PJ. 2014. Cellular and molecular mechanisms of chronic obstructive pulmonary disease. *Clin Chest Med*, 35:71-86.
- Beutler, B. 2003. INNATE IMMUNE RESPONSES TO MICROBIAL POISONS: Discovery and Function of the Toll-Like Receptors. *Annual Review of Pharmacology and Toxicology*, 43(1), hlm.609–628.
- Cekan SZ. 2004. Review: Methods to find out the expression of activated genes.

- Reproductive Biology and Endocrinology*, 2:68.
- Chastre, J. and Fagon, J. 2001. 'State of the Art Ventilator-associated Pneumonia', *Critical Care Medicine*, 1997(23), hlm. 867–903.
- Chochola J, Yamaguchi Y, Moguilevsky N, Bollen A, Strosberg AD, Stanislawski M. 1994. Virucidal effect of myeloperoxidase on human-immunodeficiency-virus type1 infected. T-cells Antimicrob Agents Chemother 38(5):969–972
- Chung KF, Adcock IM. 2008. Multifaceted Mechanisms in COPD: Inflammation, immunity, and tissue repair and destruction. *Eur Respir J*, 31: 1334-1356.
- Craig A, Mai J, Cai S, Jeyaseelan S. 2009. Neutrophil recruitment to the lungs during bacterial pneumonia. *Infection and Immunity*. vol. 77. hlm. 568-75.
- Da Silva Correia, J., Soldau, K., Christen, U., Tobias, P.S., Ulevitch, R.J. 2001. Lipopolysaccharide is in close proximity to each of the proteins in its membrane receptor complex: transfer from CD14 to TLR4 and MD-2. *J. Biol. Chem.* 276(24): 21129--21135
- Deshmane SL, Kremlev S, Amini S, Sawaya BE. 2009. Monocyte Chemoattractant Protein-1 (MCP-1): An Overview. *Journal of Interferon & Cytokine Research*, 29(6): 313-322.
- Dwiyanti, R. *et al.* 2017. 'Association of typhoid fever severity with polymorphisms NOD2, VDR and NRAMP1 Genes in endemic area, Indonesia', *Journal of Medical Sciences (Faisalabad)*, 17(3), pp. 133–139. doi: 10.3923/jms.2017.133.139.
- Efendi, Z. 2003. 'Daya Fagositosis Makrofag pada Jaringan Longgar Tubuh', *USU Digital Library*, hlm. 1–4.
- Faisal, F. *et al.* 2014. 'Penilaian Respons Pengobatan Empiris pada Pasien Rawat Inap dengan Pneumonia Komunitas Evaluation of Empirical Treatment Responsse in Hospitalized Patient Community Acquired Pneumonia', *J Respir Indo*, 34(2), hlm. 60–70.
- Fernandes FF, Dias AL, Ramos CL, Ikegaki M, de Siqueira AM, Franco MC. 2007. The "in vitro" antifungal activity evaluation of propolis G12 ethanol extract on *Cryptococcus neoformans*. *Rev. Inst. Med. Trop. Sao Paulo* 49(2):93-95.
- Franklin, G. A. *et al.* 2003. 'A novel model of pneumonia from intraperitoneal injection of bacteria', *American Journal of Surgery*, 186(5), hlm. 493–499.
- Fryer RM, Randall J, Yoshida T, Hsiao LL, Blumenstock J, Jensen KE, Dimote T,

- Jensen RV, Gullans SR. 2002. Global Analysis of Gene Expression: Methods, Interpretation, and Pitfalls. *Exp Nephrol*, 10: 64-74.
- Gantt, K. R., S. Schultz-Cherry, N. Rodriguez, S. M. Jeronimo, E. T. Nascimento, T. L. Goldman, T. J. Recker, M. A. Miller, M. E. Wilson. 2003. Activation of TGF- $\beta$  by *Leishmania chagasi*: importance for parasite survival in macrophages. *J. Immunol.*
- Garau, J. 2005. 'Role of beta-lactam agents in the treatment of community-acquired pneumonia', *European Journal of Clinical Microbiology and Infectious Diseases*, 24(2), hlm. 83–99
- Global Burden of Disease. 2013. Mortality and Causes of Death Collaborators Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet*. 2015;385:117–171.
- Goetz MB, Rhew DC, Torres A. 2005. Pyogenic bacterial pneumonia, lung abscess and empyema. In: Mason RJ, Broaddus VC, Murray JF, Nadel JA, editors. *Murray and Nadels Textbook of Respiratory Medicine*. 4th ed. Philadelphia: Elsevier Inc. hlm. 979-1032.
- GOLD. 2019. Global Initiative for Chronic Obstructive Lung Disease. Available at: [www.goldcopd.org](http://www.goldcopd.org) (Accessed: 03 September 2022)
- Hatta, M. and Smits, H. L. 2007. 'Detection of Salmonella typhi by nested polymerase chain reaction in blood, urine, and stool samples', *American Journal of Tropical Medicine and Hygiene*, 76(1), pp. 139–143. doi: 10.4269/ajtmh.2007.76.139.
- Hatta, M. *et al.* 2017. 'Expression of mRNA IL-17F and sIL-17F in atopic asthma patients', *BMC Research Notes*, 10(1), pp. 1–5. doi: 10.1186/s13104-017-2517-9.
- J.E., C. J. *et al.* 2002 'Intrapulmonary pharmacokinetics of linezolid', *Antimicrobial Agents and Chemotherapy*, 46(5), hlm. 1475–1480.
- Karakuzu Z, Iscimen R, Akalin H, Kelebek Girgin N, Kahveci F, Sinirtas M. 2018. Prognostic Risk Factors in Ventilator-Associated Pneumonia. *Med Sci Monit*. 24:1321-1328.
- Kawakami, K., M. Tohyama, K. Teruya, N. Kedeken, Q. Xie, A. Saito. 1996. Contribution of interferon  $\gamma$  in protecting mice during pulmonary and

- disseminated infection with *Cryptococcus neoformans*. *FEMS Immunol. Med. Microbiol.* 13:133.-140.
- Kemenkes RI. 2022. Profil Kesehatan Indonesia tahun 2021. Kementerian Kesehatan RI, hlm 182-184.
- KG, B. 2002. *Imunologi Dasar Edisi 5*. 5th edn. Jakarta: Balai Penerbit Fakultas Kedokteran Universitas Indonesia.
- Ko, J. and Kim, K. 2013. 'Effects of exercise and diet composition on expression of MCP-1 and oxidative stress-related mRNA of adipose tissue in diet-induced obese mice', *Journal of Exercise Nutrition and Biochemistry*, 17(4), pp. 181–188. doi: 10.5717/jenb.2013.17.4.181.
- Kresno, S. B. 2001. *Imunologi: Prosedur Diagnosis dan Laboratorium*. 4th edn. Jakarta: Fakultas Kedokteran Universitas Indonesia.
- Khan MU, Cheema Y, Shahbaz AU, Ahokas RA, Sun Y, Gerling IC, Bhattacharya SK, Weber KT. 2012. Mitochondria play a central role in nonischemic cardiomyocyte necrosis: common to acute and chronic stressor states. *Pflugers Arch* 464(1):123–131.
- Kaufmann, S. H. E. and Dorhoi, A. 2016. 'Molecular Determinants in Phagocyte-Bacteria Interactions', *Immunity*. Elsevier Inc., 44(3), hlm. 476–491.
- Lim, W. S. *et al.* 2009. 'British Thoracic Society guidelines for the management of community acquired pneumonia in adults: Update 2009', *Thorax*, 64(SUPPL. 3).
- Li, G. C. *et al.* 2012. 'TGF beta1 and related-Smads contribute to pulmonary metastasis of hepatocellular carcinoma in mice model', *Journal of Experimental and Clinical Cancer Research*, 31(1), p. 1. doi: 10.1186/1756-9966-31-93.
- Li MO, Wan YY, Sanjabi S, Robertson AL, Flavell RA. 2006. Transforming Growth Factor- $\beta$  Regulation of Immune Responses. *Annu Rev Immunol*, 24: 99-146.
- Lopes AA, Ferreira TS, Nesi RT, Lanzetti M, Pires KM, *et al.* 2013. Antioxidant action of propolis on mouse lungs exposed to short-term cigarette smoke. *Bioorganic and Medicinal Chemistry*, 21: 7570-7577.
- Lutfiyya, M. N. *et al.* 2006. 'Diagnosis and treatment of community-acquired pneumonia.', *American family physician*, 73(3), pp. 442–50.

- Maitra A, Kumar V. The lung. 2007. In: Kumar, Abbas, Fausto, Mitchell, editors. *Robbin Basic Pathology*. 8th ed. Philadelphia: Saunders Elsevier. hlm. 508- 28.
- Mandell, L. A. *et al.* 2007. 'Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults', *Clinical Infectious Diseases*, 44(Supplement\_2), hlm. S27–S72.
- Martinez R, Menedez R, Reyes S, Polverino E, Cilloniz C, Martinez A, et al. 2011. Factors associated with inflammatory cytokine patterns in community-acquired pneumonia. *Eur Respir J*. vol. 37. hlm. 393-399.
- Mason CM, Nelson S. 2005. Pulmonary host defenses and factors predisposing to lung infection. *Clin Chest Med*. vol. 26. hlm. 11-7
- Mas Rusyati, L. M. *et al.* 2020. 'Higher Treg FoxP3 and TGF- $\beta$  mRNA Expression in Type 2 Reaction ENL (Erythema Nodosum Leprosum) Patients in Mycobacterium leprae Infection', *The Open Microbiology Journal*, 14(1), pp. 304–309. doi: 10.2174/1874434602014010304.
- McDaniel, D. K., & Allen, I. C. 2019. Using Klebsiella pneumoniae to Model Acute Lung Inflammation in Mice. *Methods in Molecular Biology*, 169–180.
- Mizgerd JP. 2008. Acute lower respiratory tract infection. *N Engl J Med*. vol. 358. hlm. 716-27.
- Moldoveanu B, Otmishi P, Jani P, Walker J, Sarmiento X, Guardiola J, et al. 2009. Inflammatory mechanisms in the lung. *Journal of inflammation research*. vol.2. hlm. 1-11.
- Montuschi P, Barners PJ, Roberts LJ. 2004. Isoprostanes: markers and mediators of oxidative stress. *The FASEB Journal*. 18:1791-1797.
- Murphy PM, Baggiolini M, Charo IF, Hébert CA, Horuk R, Matsushima K, Miller LH, Oppenheim JJ, Power CA. *Pharmacol Rev*. 2000 Mar; 52(1):145-76.
- Nicod LP. 2005. Lung defences: an overview. *Eur Respir Rev*. vol. 14. hlm. 45-50.
- Niederman, M. S. 2007. 'Recent advances in community-acquired pneumonia: Inpatient and outpatient', *Chest*. The American College of Chest Physicians, 131(4), pp. 1205–1215. doi: 10.1378/chest.06-1994.
- Paczosa, M. 2016. 'Klebsiella pneumoniae: Going on the Offense with a Strong Defense Michelle', *Hamostaseologie*, 27(1), pp. 22–31. doi: 10.1128/MMBR.00078-15.Address.

- Paspuleti VR, Sammugam L, Ramesh N, Gan SH. 2017. Honey, Propolis, and Royal Jelly: A Comprehensive Review of Their Biological Actions and Health Benefits. *Hindawi Oxidative Med and Cellular Longevity*, 1:21.
- Perhimpunan Dokter Paru Indonesia (PDPI). 2014. Pneumonia komunitas. Pedomannya Diagnosis dan Penatalaksanaan di Indonesia. Jakarta: PDPI.
- Phillips-Houlbracq M, Ricard JD, Foucrier A, Yoder-Himes D, Gaudry S, Bex J, Messika J, Margetis D, Chatel J, Dobrindt U, Denamur E, Roux D. Pathophysiology of Escherichia coli pneumonia: Respective contribution of pathogenicity islands to virulence. *Int J Med Microbiol*. 2018 Mar;308(2):290-296.
- Pneumonia, H. 2005. 'Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia', *American Journal of Respiratory and Critical Care Medicine*, 171(4), pp. 388–416. doi: 10.1164/rccm.200405-644ST.
- Pohanka, M. 2013. *Role of oxidative stress in infectious diseases. A review. Folia Microbiologica*, 58(6), 503–513. doi:10.1007/s12223-013-0239-5
- Profil Kesehatan Indonesia. 2016. *Profil Kesehatan RI 2015, Profil Kesehatan Indonesia Tahun 2015*. doi: 10.1111/evo.12990.
- Purnamanita *et al.* 2020. 'The effectiveness of triamcinolone injection on risk of postoperative operations with the conjunctiva autograft technique and its association with change of VEGF mRNA Expression', *Biomedical and Pharmacology Journal*, 13(2), pp. 543–549. doi: 10.13005/bpj/1916.
- Ramadan A, Soliman G, Sawsan S. 2012. Evaluation of the safety and antioxidant activities of *Crocus sativus* and *Propolis* ethanolic extracts. *Journal of Saudi Chemical Society* 16(1):13-21.
- Ramalingam M, Kim SJ 2012. Reactive oxygen/nitrogen species and their functional correlations in neurodegenerative diseases. *J Neural Transm* 119(8):891–910. doi:10.1007/s00702-011-0758-7
- Ramos AFN, Miranda JL. 2007. Propolis: A Review of Its Anti-inflammatory and Healing Actions. *J Venom Anim Toxins incl Trop Dis*, 13(4): 697-710.
- Robinson MA, Baumgardner JE, Otto CM. 2011. Oxygen-dependent regulation of nitric oxide production by inducible nitric oxide synthase. *Free Radic Biol Med* 51(11):1952–1965
- Rodríguez-Martínez, J. M. *et al.* 2008. 'Activity of ciprofloxacin and levofloxacin in experimental pneumonia caused by *Klebsiella pneumoniae* deficient in

- porins, expressing active efflux and producing QnrA1', *Clinical Microbiology and Infection*, 14(7), pp. 691–697. doi: 10.1111/j.1469-0691.2008.02020.x.
- Romulo, A., Zuhud, E. A. M. and Rondevaldova, J. 2018. 'Screening of in vitro antimicrobial activity of plants used in traditional Indonesian medicine', *Pharmaceutical Biology*. Informa Healthcare USA, Inc, 56(1), hlm. 287–293.
- Sirait, R. H. *et al.* 2018. 'Systemic lidocaine inhibits high-mobility group box 1 messenger ribonucleic acid expression and protein in BALB/c mice after closed fracture musculoskeletal injury', *Saudi Journal of Anaesthesia*, 12(3), pp. 395–398.
- Shahin G, Behrouz L, Alireza Z, Elmira M, Mohammad M and Amir HT. 2012. Comparative effects of propolis of honey bee on pathogenic bacteria. *African Journal of Pharmacy and Pharmacology* Vol. 6(32), hlm. 2408-2412.
- Society., A. T. 1995. 'Hospital-acquired pneumonia in adults. Diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies.', *Am J Respir Crit Care Med*, 153, hlm. 1711 – 1725
- Sohn SH, *et al.* 2013. The effects of Gamijinhae-tang on elastase/lipopolysaccharide-induced lung inflammation in an animal model of acute lung injury. *BMC Complementary and Alternative Medicine*, 13:176.
- Søndergaard MJ, Friis MB, Hansen DS, Jørgensen IM. Clinical manifestations in infants and children with Mycoplasma pneumoniae infection. *PLoS One*, 13(4):e0195288.
- Soroy S, Bagus LP, Yonkie W. 2014. The effect of a unique propolis compound (Propoelix™) on clinical outcomes in patients with dengue hemorrhagic fever. *Infect Drug Resist* 7: 323–329.
- Standiford TJ, Kunkel SL, Phan SH, Rollins BJ, Strieter RM *J Biol Chem*. 1991 May 25; 266(15):9912-8.
- Sung HJ, Son SJ, Yang SJ, Rhee KJ, Kim YS. 2012. Increased expression of interleukin-1 beta in triglyceride-induced macrophage cell death is mediated by p38 MAP kinase. *BMB Rep* 45 (7):414–418.
- Surachmanto, E. E. *et al.* (2018) 'Association between asthma kontrol and Interleukin-17F expression levels in adult patients with atopic asthma', *Saudi Medical Journal*, 39(7), pp. 662–667. doi:

10.15537/smj.2018.7.22055.

- Tsunawaki, S., M. Sporn, A. Ding, C. Nathan. 1988. Deactivation of macrophages by transforming growth factor  $\beta$ . *Nature* 334:260.-262.
- Usman AN, Syam Y, Natzir R, Rahardjo SP, Hatta M, Dwiyani R, 2016. The Effect of Giving Trigona Honey and Honey Propolis Trigona to the mRNA Foxp3 Expression in Mice Balb/c Strain Induced by *Salmonella Typhi*. *American Journal of Biomedical Research*, 4(2): 42-45
- V Dimov, N Ivanovska, N Manolova, V Bankova, N Nikolov, et al. 1991, Immunomodulatory action of propolis. Influence on anti-infectious protection and macrophage /function. *Apidologie, Springer Verlag*, 22 (2)
- WHO. 2017. Pneumonia. WHO. World Health Organization. Available at: <https://www.who.int/health-topics/pneumonia> (Accessed: 03 September 2022)
- Wright JL, Churg A. 1990. Cigarette smoke causes physiologic and morphologic changes of emphysema in the Guinea pig. *Am Rev Respir Dis*, 142(6 Pt 1):1422–1428.
- Yangi B, Ustuner MC, Dincer M, Ozbayer C, Tekin N, et al. 2018. Propolis Protects Endotoxin Induced Acute Lung and Liver Inflammation Through Attenuating Inflammatory Responses and Oxidative Stress. *J Med Food*, 1-10.
- Zulhendri F, Chandrasekaran K, Kowacz M. 2021. Antiviral, Antibacterial, Antifungal, and Antiparasitic Properties of Propolis: A Review. *Food*. 10(6), 1360.



## LAMPIRAN

### HASIL PEMERIKSAAN RTPCR GEN TGF $\beta$ / HOUSEKEEPING GEN $\beta$ -ACTIN

Plate 1

NO	Sampel	Ekspresi (Fold change)
1	LB01	7,311
2	LB02	7,550
3	LB03	6,623
4	LB04	5,133
5	LB05	5,899
6	LC01	10,845
7	LC02	12,365
8	LC03	11,130
9	LC04	10,283
10	LC05	11,778
11	LD01	7,627
12	LD02	7,858
13	LD03	6,501
14	LD04	8,842
15	LD05	7,757

Plate 2

NO	Sampel	Ekspresi (Fold change)
1	LB06	5,533
2	LB07	7,161
3	LB08	6,149
4	LB09	8,018
5	LB10	7,420
6	LC06	12,517
7	LC07	9,649
8	LC08	10,601
9	LC09	11,320
10	LC10	9,390
11	LD06	14,468
12	LD07	11,939
13	LD08	13,919
14	LD09	12,928
15	LD10	13,528

Plate 3

NO	Sampel	Ekspresi (Fold change)
1	LA11	6,372
2	LA12	5,064
3	LA13	5,519
4	LA14	5,449
5	LA15	7,136
6	LB11	6,624
7	LB12	5,209
8	LB13	5,673
9	LB14	5,784
10	LB15	7,298
11	LC11	11,381
12	LC12	10,234
13	LC13	9,951
14	LC14	10,070
15	LC15	10,828
16	LD11	9,613
17	LD12	9,522
18	LD13	8,756
19	LD14	8,384
20	LD15	9,121

Plate 4

NO	Sampel	Ekspresi (Fold change)
1	LA16	5,153
2	LA17	7,409
3	LA18	5,891
4	LA19	6,555
5	LA20	6,149
6	LB16	5,340
7	LB17	7,870
8	LB18	5,922
9	LB19	6,772
10	LB20	6,252
11	LC16	11,456
12	LC17	11,167
13	LC18	10,630
14	LC19	10,340
15	LC20	10,906
16	LD16	7,638
17	LD17	8,047
18	LD18	6,043
19	LD19	7,552
20	LD20	6,965

**Hasil Pemeriksaan Mouse TGFB1 / TGF Beta 1 ELISA Kit Catalog No. LS-F5184**

**Plate 1**

No	No Sampel	Konsentrasi (pg/ml)
1	SB01	473,903
2	SC01	1051,048
3	SD01	639,086
4	SB02	607,243
5	SC02	967,461
6	SD02	728,643
7	SB03	523,657
8	SC03	1017,215
9	SD03	666,948
10	SB04	422,159
11	SC04	858,003
12	SD04	623,165
13	SB05	448,031
14	SC05	1072,939
15	SD05	649,037
16	SB06	555,499
17	SC06	935,619
18	SD06	1256,033
19	SB07	436,090
20	SC07	806,259
21	SD07	1226,181
22	SB08	505,746
23	SC08	879,894
24	SD08	1160,506
25	SB09	575,401
26	SC09	1033,136
27	SD09	1279,915
28	SB10	613,214
29	SC10	941,589
30	SD10	1059,008

**Plate 2**

No	No Sampel	Konsentrasi (pg/ml)
1	SA11	668,831
2	SB11	687,669
3	SC11	896,987
4	SD11	861,403
5	SA12	438,581
6	SB12	463,699
7	SC12	999,553
8	SD12	771,396
9	SA13	543,240
10	SB13	587,197
11	SC13	915,825
12	SD13	844,657
13	SA14	633,247
14	SB14	641,619
15	SC14	878,148
16	SD14	792,328
17	SA15	559,985
18	SB15	601,849
19	SC15	966,062
20	SD15	888,614
21	SA16	451,140
22	SB16	488,817
23	SC16	930,478
24	SD16	570,451
25	SA17	428,115
26	SB17	469,979
27	SC17	936,757
28	SD17	652,085
29	SA18	530,681
30	SB18	551,613
31	SC18	982,807
32	SD18	714,880
33	SA19	444,861
34	SB19	503,470
35	SC19	1020,484
36	SD19	693,949
37	SA20	434,395
38	SB20	467,886
39	SC20	1007,925
40	SD20	608,128

**HASIL PEMERIKSAAN RTPCR GEN MCP1 / HOUSEKEEPING GEN GAPDH**

PLATE 1  
PLATE 2

NO	Sampel	Ekspresi (Fold change)
1	LB01	8,118
2	LB02	7,441
3	LB03	5,727
4	LB04	8,321
5	LB05	7,180
6	LC01	12,819
7	LC02	12,482
8	LC03	11,948
9	LC04	11,670
10	LC05	10,532
11	LD01	8,988
12	LD02	8,575
13	LD03	7,949
14	LD04	9,239
15	LD05	8,808

NO	Sampel	Ekspresi (Fold change)
1	LB06	6,707
2	LB07	6,259
3	LB08	5,963
4	LB09	8,619
5	LB10	6,548
6	LC06	11,288
7	LC07	10,874
8	LC08	13,155
9	LC09	10,441
10	LC10	10,971
11	LD06	12,605
12	LD07	14,176
13	LD08	14,303
14	LD09	15,365
15	LD10	12,712

PLATE 3

NO	Sampel	Ekspresi (Fold change)
1	LA11	6,199
2	LA12	6,827
3	LA13	8,542
4	LA14	8,229
5	LA15	7,283
6	LB11	6,507
7	LB12	7,039
8	LB13	8,726
9	LB14	8,660
10	LB15	7,421
11	LC11	11,835
12	LC12	11,484
13	LC13	10,942
14	LC14	11,686
15	LC15	10,722
16	LD11	10,334
17	LD12	9,759
18	LD13	10,636
19	LD14	10,277
20	LD15	9,411

PLATE 4

NO	Sampel	Ekspresi (Fold change)
1	LA16	6,925
2	LA17	6,137
3	LA18	5,966
4	LA19	5,707
5	LA20	6,767
6	LB16	7,374
7	LB17	8,332
8	LB18	6,323
9	LB19	5,874
10	LB20	7,157
11	LC16	11,288
12	LC17	11,062
13	LC18	10,441
14	LC19	10,858
15	LC20	10,578
16	LD16	7,956
17	LD17	8,885
18	LD18	7,514
19	LD19	8,400
20	LD20	7,623

**Hasil Pemeriksaan Mouse CCL2 / MCP1 ELISA Kit Catalog No. LS-F37063**

**Plate 1**

No	No Sampel	Konsentrasi (pg/ml)
1	SB01	292,837
2	SB02	382,554
3	SB03	488,963
4	SB04	609,977
5	SB05	539,037
6	SB06	589,112
7	SB07	420,110
8	SB08	326,220
9	SB09	255,281
10	SB10	449,320
11	SC01	833,226
12	SC02	964,672
13	SC03	785,238
14	SC04	1087,773
15	SC05	1033,525
16	SC06	916,684
17	SC07	893,733
18	SC08	864,523
19	SC09	993,883
20	SC10	1008,488
21	SD01	660,051
22	SD02	568,248
23	SD03	507,741
24	SD04	705,953
25	SD05	618,322
26	SD06	1206,700
27	SD07	1058,562
28	SD08	1171,230
29	SD09	1327,714
30	SD10	1075,254

**Plate 2**

No	No Sampel	Konsentrasi (pg/ml)
1	SA11	525,163
2	SA12	329,215
3	SA13	391,752
4	SA14	260,425
5	SA15	416,767
6	SA16	383,414
7	SA17	568,939
8	SA18	379,245
9	SA19	527,248
10	SA20	387,583
11	SB11	550,178
12	SB12	356,315
13	SB13	400,090
14	SB14	264,594
15	SB15	466,796
16	SB16	433,443
17	SB17	575,193
18	SB18	408,428
19	SB19	558,516
20	SB20	441,781
21	SC11	912,890
22	SC12	825,339
23	SC13	785,733
24	SC14	867,030
25	SC15	948,328
26	SC16	794,071
27	SC17	846,185
28	SC18	858,692
29	SC19	892,045
30	SC20	996,273
31	SD11	706,520
32	SD12	662,744
33	SD13	656,490
34	SD14	771,141
35	SD15	694,012
36	SD16	485,557
37	SD17	612,715
38	SD18	508,487
39	SD19	621,053
40	SD20	498,064



**REKOMENDASI PERSETUJUAN ETIK**

Nomor : 336/UN4.6.4.5.31/ PP36/ 2021

Tanggal: 21 Mei 2021

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH21040271	No Sponsor Protokol	
Peneliti Utama	<b>dr. Feni Fitriani Taufik, SpP(K)</b>	Sponsor	
Judul Peneliti	Ekspresi mRNA GEN TGF- $\beta$ , MCP-1 dan SOLUBLE PROTEIN TGF- $\beta$ , MCP-1 pada Mencit yang Diinduksi Klebsiela Pneumoniae Setelah Pemberian Propolis		
No Versi Protokol	<b>1</b>	Tanggal Versi	<b>29 April 2021</b>
No Versi PSP		Tanggal Versi	
Tempat Penelitian	Laboratorium Biologi Molekuler dan Imunologi Fakultas Kedokteran Universitas Hasanuddin Makassar		
Jenis Review	<input type="checkbox"/> Exempted <input checked="" type="checkbox"/> Expedited <input type="checkbox"/> Fullboard Tanggal	Masa Berlaku <b>21 Mei 2021</b> sampai <b>21 Mei 2022</b>	Frekuensi review lanjutan
Ketua Komisi Etik Penelitian Kesehatan FKUH	Nama <b>Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)</b>	Tanda tangan 	
Sekretaris Komisi Etik Penelitian Kesehatan FKUH	Nama <b>dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)</b>	Tanda tangan 	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 jam dan dilengkapi dalam 7 hari dan Laporan SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari prokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan